AngioSafe Peripheral CTO Crossing System Study (RESTOR-1 Study)

Launched by ANGIOSAFE, INC. · Dec 5, 2020

Keywords

ClinConnect Summary

The purpose of the study is to demonstrate the safety and effectiveness of the AngioSafe Peripheral CTO Crossing System. The system facilitates the crossing of chronic total occlusions (CTOs) in the peripheral arteries of lower limbs. A minimum of 70 subjects will be treated across selected study enters within the U.S. and followed for 30 days.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Able and willing to comply with protocol requirements and sign informed consent form
• • ≥ 22 years of age
• • Peripheral arterial disease defined by Rutherford Clinical Classification (Category 2-5)
• • Peripheral artery disease in target extremity is confirmed by imaging (catheter angiography, computed tomographic angiography (CTA), and/or magnetic resonance angiography (MRA))
• Angiographic Inclusion Criteria:
• • Target lesion in native de novo common femoral artery (CFA), superficial femoral artery (SFA), and/or popliteal artery
• • Vessel diameter(s) for target lesion is ≥ 3.0mm and ≤ 10mm
• • Subject's target lesion is a severely stenosed segment of ≤ 300 mm that involves the CTO(s)
• • Subject's target lesion involves at least one CTO that is 99-100% stenosed
• • Subject has at least one vessel with run-off to the foot
• Exclusion Criteria:
• • Systemic infection or an infection in extremity of target lesion
• • Target lesion within native vein or synthetic vessel grafts or in stent occlusion
• • Planned intervention in the contralateral limb during the study
• • Planned intervention in the target limb of the inflow vessels during the study
• • Planned intervention of lower extremities after study procedure within 30-day follow-up visit
• • Coagulopathy or bleeding diatheses, thrombocytopenia with platelet count less than 50,000/μl, or INR \> 1.7
• • Antiplatelet, anticoagulant, or thrombolytic therapy is contraindicated
• • Allergy to contrast agents or medications used to perform endovascular intervention that cannot be adequately pre-treated
• • Allergy to nickel, titanium, urethane, nylon, or silicone
• • History of myocardial infarction within 30 days prior to enrollment/consent
• • History of stroke within 30 days prior to enrollment/consent
• • Chronic kidney disease (CKD) of stage 4 or greater based on an Estimated Glomerular Filtration Rate (eGFR) \<30ml/Min, unless the subject is on chronic renal replacement therapy
• • Hemoglobin levels \<10g/dL verified by a lab test no older than 14 days prior to enrollment, unless the subject has a history of chronic anemia at a stable level, no recent bleeding diathesis or history of blood transfusion in the last six weeks
• • Pregnant or nursing, for females of child-bearing potential (\< 50 years of age)
• • Participating in another interventional research study that may interfere with study endpoints
• • Prior major amputation (above ankle) in target extremity
• • Acute limb ischemia (ALI)
• • Prior unsuccessful attempt to cross the target lesion
• • Subject has had a procedure on the target limb or contralateral limb within 7 days
• • Subject has had a procedure on the target limb or contralateral limb within the past 30 days and is unstable